Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update

Go back to Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update

Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

November 10, 2016 7:35 AM EST

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.02 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

... More